相关临床试验
93
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1903
已完成
72
77.4%
终止
17
18.3%
撤回
4
4.3%
暂无批准数据
- The American Academy of Sleep Medicine advocates for permanent standard time, arguing it best aligns with human circadian biology and natural morning light cues. - Studies link social jet lag—the misalignment between social clocks and solar time—to increased risks of obesity, diabetes, cardiovascular disease, and shorter sleep duration. - A 2019 Journal of Health Economics study found that people living farther west within a time zone had worse health outcomes due to chronic circadian disruption. - The Sunshine Protection Act, which would make daylight saving time permanent, raises concerns about darker winter mornings and children commuting to school before sunrise.
- The FDA approved Evita Solutions' generic version of mifepristone in September, sparking controversy among lawmakers and pro-life advocates. - Senate Health, Education, Labor and Pensions Committee held a contentious hearing examining the safety protocols for mifepristone distribution. - Republican senators called for restoration of in-person dispensing requirements, while Democrats defended the drug's safety profile. - FDA Commissioner Marty Makary faces criticism for allegedly slow-walking a comprehensive safety review of mifepristone.
- Indiana University School of Medicine researchers received a five-year, $11.3 million NIH grant to develop SHIP1 inhibitors targeting the INPP5D gene, which acts as a brake on microglia function in Alzheimer's disease. - The TREAT-AD drug discovery center has narrowed down hundreds of potential drug targets to five promising candidates, with SHIP1/INPP5D leading as the most advanced therapeutic target. - Researchers aim to optimize small molecules that block SHIP1 protein, potentially making microglia more effective at clearing harmful amyloid plaques in the brain. - The team will test inhibitors in Alzheimer's mouse models and develop biomarkers to track drug activity and effectiveness for future clinical trials in humans.
- Cumberland Pharmaceuticals' Phase 2 FIGHT DMD trial demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction compared to control groups. - The study showed reduced blood levels of cardiac damage markers (NT-proBNP and cardiac troponin I) in patients receiving ifetroban, while these markers increased in placebo-treated patients. - Ifetroban represents a potential breakthrough for DMD heart disease, which is the leading cause of death in DMD patients and currently has no approved targeted treatments. - All patients who completed the 12-month study opted to continue with the open-label extension, demonstrating confidence in the treatment approach.
- New research presented at ATS 2025 reveals that sleep patterns in ICU patients may serve as important biomarkers for predicting patient outcomes, with atypical N3 sleep linked to longer ICU stays. - A study of ICU patients found that hypersomnia (sleeping more than 11 hours in 24 hours) was associated with higher mortality rates, longer hospital stays, and lower rates of discharge to home. - Over 60% of ICU survivors with acute respiratory failure experience insomnia, with pre-existing mental health conditions and neurologic causes of respiratory failure significantly increasing this risk.
- A pilot study of 15 women demonstrated that once-weekly oral secnidazole granules reduced bacterial vaginosis recurrence to 20% over 28 weeks, compared to CDC-recommended treatments with 35-70% recurrence rates. - The simplified treatment protocol addresses patient compliance barriers associated with current complex regimens that require daily dosing for multiple days or intravaginal applications. - Secnidazole's superior oral absorption and longer elimination half-life compared to metronidazole may contribute to its effectiveness in suppressive therapy for recurrent bacterial vaginosis. - The findings support potential expansion of secnidazole use beyond acute bacterial vaginosis treatment to long-term management of recurrent cases.
- Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment. - Patients receiving Olumiant required significantly less insulin therapy and experienced decreased blood glucose fluctuations compared to placebo, potentially reducing treatment burden. - Researchers identify TYK2 inhibition as another promising approach for type 1 diabetes treatment, with an FDA-approved psoriasis drug potentially offering a dual mechanism to protect beta cells and reduce inflammation.
- GLP-1 receptor agonist use has increased dramatically among type 1 diabetes patients, with prescriptions rising from 4% to 33% in severely obese adults over the past decade. - Obesity rates have climbed significantly in the type 1 diabetes population, increasing from 18% to 26% in children and from 30% to 38% in adults between 2008 and 2023. - Researchers from Johns Hopkins emphasize the urgent need for clinical trial data on GLP-1 drugs in type 1 diabetes patients, as these medications are not FDA-approved for this population and may pose hypoglycemia risks.
- Retroperitoneal lymph node dissection (RPLND) is emerging as an effective treatment for early-stage II seminoma, potentially reducing reliance on chemotherapy. - Studies show RPLND yields 2-year recurrence-free survival rates of 70-90% without adjuvant therapy, influencing updated AUA and NCCN guidelines. - Most recurrences post-RPLND occur within two years, emphasizing the need for vigilant surveillance and the effectiveness of salvage chemotherapy. - Refinements in RPLND techniques have led to fewer complications and shorter hospital stays, enhancing its viability as a primary treatment option.
